================================================================================

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 10-Q

       Quarterly report pursuant to Section 13 or 15(d) of the Securities
         Exchange Act of 1934. For the quarter ended September 30, 1996.

                         Commission file number 1-11388


                                PLC SYSTEMS INC.
             (Exact name of registrant as specified in its charter)


BRITISH COLUMBIA, CANADA                                 04-3153858
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
 incorporation or organization)

10 FORGE PARK, FRANKLIN, MASSACHUSETTS                     02038
(Address of principal executive offices)                 (Zip Code)

       Registrant's telephone number, including area code: (508) 541-8800

                                   ----------

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.
 YES [X] NO [ ].



                     APPLICABLE ONLY TO CORPORATE ISSUERS:


Indicate  the  number of shares  outstanding  of each of the  issuer's  class of
common stock, as of the latest practical date.

             Class                             Outstanding at November 13, 1996
             -----                             --------------------------------
   Common Stock, no par value                             16,511,807







================================================================================

                                PLC SYSTEMS INC.

                                      INDEX



Part I.  Financial Information:

         Item 1.

               Consolidated Condensed Balance Sheets..........................3

               Consolidated Condensed Statements of Operations................4

               Consolidated Condensed Statements of Cash Flows................5

               Notes to Consolidated Condensed Financial Statements...........6


         Item 2.  Management's Discussion and Analysis
                    of Financial Condition and Results of Operations.......7-10


Part II.     Other Information:

         Item 1.    Legal Proceedings........................................11

         Item 2.    Changes in Securities....................................11

         Item 3.    Defaults by the Company Upon its Senior Securities.......11

         Item 4.    Submission of Matters to a Vote of Security Holders......11

         Item 5.    Other Information........................................11

         Item 6.    Exhibits and Reports on Form 8-K..................... 11-12


                                      -2-





ITEM 1.  FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------

                                PLC SYSTEMS INC.
                      CONSOLIDATED CONDENSED BALANCE SHEETS
                                 (In thousands)




                                                                           September 30,       December 31,
                                                                               1996               1995
                                                                           -----------         -----------
                                                                            (Unaudited)
                                                                                              

                                     ASSETS
Current assets:
    Cash and cash equivalents ..........................................       $ 4,169             $   704
    Short-term investments .............................................         7,472               6,500
    Accounts receivable, net ...........................................           863               6,749
    Inventories, net ...................................................         3,199               1,789
    Prepaid expenses and other current assets ..........................         1,241                 488
                                                                               -------             -------
        Total current assets ...........................................        16,944              16,230

Equipment, furniture and leasehold improvements, net ...................         3,382               1,692
Other assets ...........................................................           370                 368
                                                                               -------             -------
       Total assets ....................................................       $20,696             $18,290
                                                                               =======             =======


                                         LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
    Accounts payable ....................................................     $  1,176            $    546 
    Accrued clinical costs ..............................................          958                 854
    Accrued compensation ................................................          178                 777
    Deferred revenue ....................................................           96                 166
    Other accrued liabilities ...........................................          338                 346
                                                                              --------            --------
       Total current liabilities ........................................        2,746               2,689
                                                                                          
Deferred revenue ........................................................          230                  61
Capital lease obligations ...............................................           25                  32
Commitments and contingencies                                                             
                                                                                          
Stockholders' equity:                                                                     
Common stock, no par value,  25,000 shares authorized,                                    
 16,510 and 15,944 shares issued and outstanding in 1996                                  
 and 1995,  respectively ................................................       54,004              51,411
Accumulated deficit .....................................................      (35,778)            (35,589)
Foreign currency translation ............................................         (531)               (314)
                                                                              --------            --------
                                                                                17,695              15,508
                                                                              --------            --------
Total liabilities and stockholders' equity ..............................     $ 20,696            $ 18,290
                                                                              ========            ========

                                                                             
                                                                              
               The accompanying notes are an integral part of the
                  consolidated condensed financial statements.


                                       -3-




                                PLC SYSTEMS INC.
                 CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
                      (In thousands, except per share data)






                                                     Three Months Ended               Nine Months Ended
                                                        September 30,                   September 30,
                                                     ------------------               -----------------

                                                    1996            1995             1996            1995
                                                    ----            ----             ----            ----

                                                                                    
Revenues:
  Product sales ..............................   $      1,802    $      1,174    $      6,768    $      5,052
  Placement and service fees .................            691             417           1,985             895
                                                 ------------    ------------    ------------    ------------
    Total revenues ...........................          2,493           1,591           8,753           5,947

Cost of revenues:
  Product sales ..............................            676             818           1,936           2,474
  Placement and service fees .................            233             143             739             195
                                                 ------------    ------------    ------------    ------------
     Total cost of revenues ..................            909             961           2,675           2,669

Gross profit .................................          1,584             630           6,078           3,278

Operating expenses:
  Selling, general and administrative ........          1,555           1,114           4,597           3,241
  Research and development ...................            725             458           2,043           1,716
                                                 ------------    ------------    ------------    ------------
    Total operating expenses .................          2,280           1,572           6,640           4,957
                                                 ------------    ------------    ------------    ------------

Loss from operations .........................           (696)           (942)           (562)         (1,679)

Other income:
  Interest income, net .......................            123             153             422             475
  Gain (loss) from foreign currency, net......             11            --               (44)           --
                                                 ------------    ------------    ------------    ------------
                                                          134             153             378             475
                                                 ------------    ------------    ------------    ------------

Loss before income taxes .....................           (562)           (789)           (184)         (1,204)
Provision for income taxes ...................           --              --                 4            --
                                                 ------------    ------------    ------------    ------------
Net loss .....................................   $       (562)   $       (789)   $       (188)   $     (1,204)
                                                 ============    ============    ============    ============

Net loss per share ...........................   $      (0.03)   $      (0.05)   $      (0.01)   $      (0.08)

Shares used to compute net loss
  per share ..................................     16,499,000      15,867,000      16,331,000      15,854,000




               The accompanying notes are an integral part of the
                  consolidated condensed financial statements.

                                       -4-






                                PLC SYSTEMS INC.
                 CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
                                 (In thousands)




                                                                 Nine Months Ended
                                                                    September 30,
                                                                    -------------
                                                                   1996      1995
                                                                   ----      ----
                                                                    
Operating activities:
   Net loss ................................................   $   (188)   $ (1,204)

     Adjustments to reconcile net loss to net cash provided
    (used) for operating activities:
      Depreciation and amortization ........................        854         329
       Change in assets and liabilities:
         Decrease (increase) in accounts receivable ........      5,886        (531)
         Increase in inventory .............................     (1,410)     (1,014)
         Increase in prepaid expenses and other assets .....       (777)       (301)
         Increase in accounts payable ......................        629         346
         Increase (decrease) in deferred revenue ...........        100          68
         (Decrease) increase in accrued liabilities ........       (504)        419
                                                               --------    --------
Net cash provided (used) for operating activities ..........      4,590      (1,888)

Investing activities:
   Purchase of short-term investments ......................    (18,444)     (7,000)
    Maturities of short-term investments ...................     17,472       7,858
   Purchase of fixed assets ................................     (2,522)     (1,037)
                                                               --------    --------
Net cash used for investing activities .....................     (3,494)       (179)

Financing activities:
    Net proceeds from sales of shares ......................      2,483         181
   Repayment of stockholder notes ..........................        110          56
   Principal payments on capital lease obligations .........         (7)        (15)
                                                               --------    --------
Net cash provided by (used) financing activities ...........      2,586         222

Effect of exchange rate changes on cash and cash equivalents       (217)          2
                                                               --------    --------
Net increase (decrease) in cash and cash equivalents .......      3,465      (1,843)

Cash and cash equivalents at beginning of period ...........        704       3,699
                                                               --------    --------
Cash and cash equivalents at end of period .................   $  4,169    $  1,856
                                                               ========    ========



               The accompanying notes are an integral part of the
                  consolidated condensed financial statements.

                                       -5-






                                PLC SYSTEMS INC.
              NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS



1.        BASIS OF PRESENTATION

         The  balance  sheet as of  September  30,  1996 and the  statements  of
operations and cash flows for the nine months ended  September 30, 1996 and 1995
are unaudited and in the opinion of management,  all adjustments necessary for a
fair  presentation  of  such  financial  statements  have  been  recorded.  Such
adjustments consisted only of normal recurring items.

         Certain  information  and  footnote  disclosures  normally  included in
financial  statements  prepared in accordance with generally accepted accounting
principles have been condensed or omitted.  The year-end  balance sheet data was
derived  from audited  financial  statements,  but does not include  disclosures
required by generally accepted accounting principles. It is suggested that these
interim  financial  statements be read in  conjunction  with the Company's  most
recent Form 10-K and Annual Report as of December 31, 1995.

2.    NET LOSS PER SHARE

         The net loss per share is calculated  using the weighted average number
of shares  outstanding  during the period and does not include share equivalents
as their inclusion would be antidilutive.

3.       INVENTORIES

         Inventories consist of the following (in thousands):

                                            September 30,       December 31,
                                                1996                1995
                                             ----------        -------------
               Raw materials                    $1,445            $   644
               Work in process                   1,038                 56
               Finished goods                      716              1,089
                                                ------             ------
                                                $3,199             $1,789
                                                ======             ======

4.  STOCK WARRANTS

         On March 8, 1996,  the Company's  Form S-3 to register the common stock
underlying  the warrants  issued to the  Company's  1992  underwriters  and 1994
placement   agent  was  declared   effective  by  the  Securities  and  Exchange
Commission.  The warrant issued to the underwriters provided for the purchase of
145,000  shares at $6.00 per share and  72,500  shares at $4.80 per  share.  The
warrant  issued to the  placement  agent  provided  for the  purchase of 150,000
shares at $3.94 per share.  At September 30, 1996,  all of the placement  agents
shares  and all  but  16,770  of the  underwriters  shares  had  been  purchased
generating approximately $1,660,000 in proceeds.

                                       -6-





 Item 2.
- --------------------------------------------------------------------------------

                                PLC SYSTEMS INC.
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS


OVERVIEW

         The Company has two  marketing  strategies  for selling the Heart Laser
and its related  components and sterile kits;  placement and sales. In countries
where health care is reimbursed by the  government or by private  insurers,  the
Company's  strategy is to be reimbursed  for the use of the Heart Laser on a per
procedure basis under a contractual  agreement whereby the customer commits to a
minimum number of procedures on a yearly basis.  These  contracts  typically run
for a  minimum  of  three  years  and  allow  for the  customer  to  exceed  the
contractual minimums.  These contracts,  referred to as placement contracts, are
preferred  to the sale  strategy  as the  Company  believes  that the  potential
revenue  stream is greater and more  profitable.  Sterile  handpieces  and other
disposables are included in the per procedure fee. Revenues from these contracts
are classified as placement fees.

         In countries  where health care is not  reimbursed by the government or
insurance,  or where  credit  risk is high,  the Heart  Laser is sold as capital
equipment and the related  sterile  handpieces  and other  disposables  are sold
separately  for each  procedure.  The Company  sells Heart  Lasers  directly and
through distributors. These sales are classified as product sales.

RESULTS OF OPERATIONS

         Total  revenues  for the three  months  ended  September  30, 1996 were
$2,493,000,  an increase of 57% when compared to $1,591,000 for the three months
ended September 30, 1995. Product sales for the three months ended September 30,
1996 were  $1,802,000,  an increase of 53% when compared to  $1,174,000  for the
three  months  ended  September  30,  1995.  Total  revenues  and product  sales
increased as the Company  recognized  revenue on three units in the three months
ended September 30, 1996 compared to two units in the period ended September 30,
1996.

         Total revenues for the nine month period ended  September 30, 1996 were
$8,753,000,  an increase of 47% when compared to $5,947,000  for the nine months
ended  September  30,  1995.  Product  sales  for the nine  month  period  ended
September  30,  1996  were  $6,768,000,  an  increase  of 34% when  compared  to
$5,052,000  for the nine months ended  September 30, 1995.  The major factors in
both of these year to date  increases are the number of Heart Lasers shipped and
the method of sale. In 1996,  there were 17 Heart Lasers shipped;  nine of which
were sales as compared with 14 shipped in 1995, seven of which were sales.

         Another  factor  in both the  three and nine  month  increase  in total
revenues is the increase in placement  and service  fees.  Placement and service
fees for the three and nine months ended

                                       -7-




                                PLC SYSTEMS INC.
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                                   (Continued)


September 30, 1996 were $691,000 and  $1,985,000,  respectively,  an increase of
66% and 122% when  compared  with  $417,000 and $895,000 for the same periods in
fiscal 1995. These significant increases reflect the continued acceptance of the
Company's preferred method of sale; the placement contract,  which has more than
doubled over the past twelve months.

         Total gross  profit for the three and nine months ended  September  30,
1996  approximated  64%  and  69%,  respectively,  up  from  40% and 55% for the
comparable  periods in fiscal  1995.  These  respective  increases  of 24 and 14
percentage  points  reflect the higher  margins  associated  with the  increased
number of direct sales of Heart  Lasers in 1996 coupled with the higher  margins
generated under placement contracts.

         Selling,  general and  administrative expenditures  were $1,555,000 and
$4,597,000   for  the  three  and  nine  months   ending   September  30,  1996,
respectively, an increase of 40% and 42% when compared to the comparable periods
in fiscal 1995 of $1,114,000 and $3,241,000.  More than a third of each of these
respective  increases  of  $441,000  and  $1,356,000  are a  reflection  of  the
investment the Company has made in its international sales and marketing efforts
in Europe and the  Pacific  Rim for both the three and nine month  periods.  The
balance of the  increases  for the three and nine month  periods  are related to
increased  domestic  staffing  and  related  operating  expenses,  coupled  with
increased spending for consultants.

         Research  and  development  expenditures  for the three and nine months
ended September 30, 1996 was $725,000 and $2,043,000,  respectively, an increase
of 58% and 19% when compared to research spending of $458,000 and $1,716,000 for
the comparable  periods in fiscal 1995. These  respective  increases of $267,000
and $327,000 reflect the increased staffing requirements associated with growing
demands for clinical study  compilation  and increased  spending for consultants
related to health care reimbursement of the TMR procedure.

         For the three and nine months ended September 30, 1996, interest income
of $123,000 and  $422,000,  respectively,  decreased  slightly  when compared to
$153,000 and $475,000 for the comparable periods in fiscal 1995. These decreases
were related to lower  interest rates  throughout  both the three and nine month
periods  in 1996 as  compared  to the  comparable  periods  in  1995.  With  the
establishment  of the  Company's  subsidiary in Germany,  currency  fluctuations
between the German  deutschmark  and the US dollar,  have  resulted in a $11,000
gain for the three  months ended  September  30, 1996 and a year to date loss of
$44,000.

         The Company  reported a net loss of $562,000 and $188,000 for the three
and nine months ended September 30, 1996, respectively. In addition, the Company
believes it has sufficient net operating  loss  carryforwards  to offset taxable
income,  if any,  for the fiscal  year ended  December  31,  1996.  The  Company
recorded an income tax provision for the three months ended March 31,

                                       -8-




                                PLC SYSTEMS INC.
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                                   (Continued)



1996 to cover the tax liability  under the  alternative  minimum tax regulations
which  can not be  offset  by net  operating  loss  carryforwards.  The  Company
believes the provision for the nine months ended September 30, 1996 is adequate,
and accordingly,  did not record a provision in the three months ended September
30, 1996.

         The net loss of $562,000 for the three months ended  September 30, 1996
decreased  29% when  compared to the net loss of $789,000  for the three  months
ended  September 30, 1995.  For the nine months ended  September  30, 1996,  the
Company had a net loss of $188,000 as compared with a net loss of $1,204,000 for
the nine months ended September 30, 1995. The  improvements for both periods are
directly  related to the  increase  in Heart  Laser  sales  offset by  increased
operating expenses as previously discussed.

         The Company continued to expand its  international  operations with the
incorporation  of two  wholly-owned  subsidiaries,  PLC  Medical  Systems  AG in
Switzerland and PLC Medical Systems Asia/Pacific Pte Ltd. in Singapore.

LIQUIDITY AND CAPITAL RESOURCES

         At September  30, 1996,  the Company had cash and cash  equivalents  of
$4,169,000  and short-term  investments  of  $7,472,000.  During the nine months
ended  September 30, 1996, cash provided by operations  approximated  $4,600,000
from the  collection  of  $5,900,000  of accounts  receivable,  principally  the
$5,700,000 IMATRON Japan contract offset by investment in inventory. The Company
received  approximately  $1,660,000  in  proceeds  from  the  exercise  of stock
warrants  coupled with  $823,000 in proceeds  from the exercise of stock options
and  $110,000  from  the  repayment  of  shareholder  loans.  The  Company  used
$2,500,000 to acquire capital equipment, principally related to an investment in
the  placement  lasers  coupled  with  leasehold  improvements  related  to  the
Company's  new  facility.  In  addition,  the  Company  invested  an  additional
$1,000,000 in short-term  investments.  On September 3, 1996,  the Company moved
into its new facility in  Franklin,  Massachusetts  under a five year  operating
lease totaling approximately $1,482,000.

         The Company believes that existing cash balances are sufficient to meet
working  capital and  capital  expenditure  requirements  through  fiscal  1997.
However,  unanticipated decreases in operating revenues or increases in expenses
may adversely impact the Company's cash position. In the future, the Company may
seek  additional   financing  through  issuance  and  sale  of  debt  or  equity
securities,  bank financing,  joint ventures or other means. The availability of
such  financing  and the  reasonableness  of any related  terms in comparison to
market conditions cannot be assured.


                                       -9-




                                PLC SYSTEMS INC.
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                                   (Continued)


         The Company believes that periodic  operating losses are possible until
after  such  time as the  Company  receives  its PMA from the FDA for the  Heart
Laser.  The Company  submitted its PMA  application in April 1995.  Although the
Heart  Laser has been  granted  "expedited  review"  status by the Food and Drug
Administration  ("FDA"), given the current uncertainties of the time required by
the FDA to approve a Premarket Approval ("PMA") application,  the Company cannot
project when, if at all,  such  approval  would be granted.  Until PMA approval,
future  profitability  will likely be determined by the number of  international
shipments and the related mix of sales and placements.

         In addition,  the Company must also  successfully  obtain approval from
the FDA for sale of the Heart  Laser in the  United  States,  obtain  regulatory
approval from and market the Heart Laser in certain  additional foreign markets,
and  convince  health care  professionals,  third  party  payors and the general
public of the medical and economic benefits of the Heart Laser. No assurance can
be given that the Company will be  successful  in  marketing  the Heart Laser or
that the Company will be able to operate  profitably  on a consistent  quarterly
basis.


                                      -10-




                                PLC SYSTEMS INC.
                            Part II Other Information



ITEM 1.  LEGAL PROCEEDINGS.

           In September 1996, as previously reported,  CardioGenesis Corporation
           ("CardioGenesis") filed a civil lawsuit in the United States District
           Court seeking to have a certain  patent of the Company's  subsidiary,
           PLC Medical  Systems,  Inc. ("PLC Medical") U.S. Patent No. 5,125,926
           declared invalid,  or,  alternatively,  asking the court to determine
           whether  CardioGenesis  infringes  PLC Medical's  patent.  In October
           1996,  the Company and PLC Medical  filed an answer and  counterclaim
           alleging that  CardioGenesis  is infringing U.S. Patent No. 5,125,926
           issued to PLC Medical.  The counterclaim seeks both injunctive relief
           and monetary damages against CardioGenesis.

ITEM 2.  CHANGES IN SECURITIES

           None

ITEM 3.  DEFAULTS BY THE COMPANY UPON ITS SENIOR SECURITIES

           None

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS.

           None

ITEM 5.  OTHER INFORMATION

           None

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

           a.) Exhibits

             (I) The following exhibits are filed herewith:

             Exhibit
                No.                             Title
             -------                            -----

              11          Statement re computation of per-share earnings.

           b.)  Reports on Form 8-K. The Company filed a Current  Report on Form
                8-K on September 25, 1996,  reporting  information  contained in
                the Company's press release


                                      -11-




               with   respect  to  the   notification   of  the  Food  and  Drug
               Administration  allowing the Company to halt the randomization of
               patients to medical  management in  multi-center  Transmyocardial
               Revascularization clinical trials.

               The Company  also  reported a copy of a Complaint  for  declaring
               relief of patent invalidity and non-infringement  filed September
               10, 1996, CardioGenesis Corporation vs. PLC Systems Inc.


                                      -12-





                                PLC SYSTEMS INC.
                            Part II Other Information
                                   (Continued)






SIGNATURES

       Pursuant to the requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.




                                                     PLC SYSTEMS INC.
                                                     Registrant



Date:    November 14, 1996                             /s/  Patricia L. Murphy
      -------------------------                      -------------------------
                                                     Patricia L. Murphy
                                                     (Chief Financial Officer)




                                      -13-







                                                                      EXHIBIT 11

                                PLC SYSTEMS INC.
                        CALCULATION OF NET LOSS PER SHARE






                                              Three Months Ended                   Nine Months Ended         
                                                   September 30,                       September 30,
                                            -------------------------             ------------------
                                            1996               1995               1996             1995
                                            ----               ----               ----             ----
                                                                             
                                                                                    
Weighted average number of                                                   
common shares outstanding ..               16,499,000      15,867,000            16,331,000      15,854,000
                                                                             
Common stock equivalents (1)                     --              --                    --              --
                                         ------------    ------------          ------------    ------------
                                                                             
Shares used to compute net                                                   
loss per share .............               16,499,000      15,867,000            16,331,000      15,854,000
                                                                             
Net loss ...................             $   (562,000)   $   (789,000)         $   (188,000)   $ (1,204,000)
                                                                             
                                                                             
Net loss per share .........             $      (0.03)   $      (0.05)         $      (0.01)   $      (0.08)
                                                                             

                                                                             
                                                                       
(1)  The net loss per share is calculated  using the weighted  average number of
     shares  outstanding  during the period and does not  include  common  stock
     equivalents as their inclusion would be antidilutive.